Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial

Although sofosbuvir has been approved for patients with genotypes 2/3 (G2/3), many parts of the world still consider pegylated Interferon alpha (P) and ribavirin (R) as standard of care for G2/3. Patients with rapid virological response (RVR) show response rates >80%. However, SVR (sustained viro...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidrich, Benjamin, Cordes, Hans-Jörg, Klinker, Hartwig, Möller, Bernd, Naumann, Uwe, Rössle, Martin, Kraus, Michael R., Böker, Klaus H., Roggel, Christoph, Schuchmann, Marcus, Stoehr, Albrecht, Trein, Andreas, Hardtke, Svenja, Gonnermann, Andrea, Koch, Armin, Wedemeyer, Heiner, Manns, Michael P., Cornberg, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461366/
https://www.ncbi.nlm.nih.gov/pubmed/26057627
http://dx.doi.org/10.1371/journal.pone.0128069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461366/
https://www.ncbi.nlm.nih.gov/pubmed/26057627
http://dx.doi.org/10.1371/journal.pone.0128069

Ejemplares similares